IP Library › Granted Patent US 12,466,871
Granted Patent B2
US 12,466,871 · App. 17/494,610 · Granted Nov 11, 2025

Fusion protein for use in the treatment of HVG disease

Inventors: Elmar Jäckel (Hannover, DE); Fatih Noyan (Hannover, DE); Michael Hust (Braunschweig, DE)
Assignees: Medizinische Hochschule Hannover; Technische Universität Braunschweig
C07K14/7051A61K40/11A61K40/22A61K40/31A61K40/416A61K40/418A61P37/06C07K16/2833C07K19/00C12N15/85A61K2039/505A61K2239/38C07K2317/622C07K2319/00C07K2319/03C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,871
App. No.
17/494,610
Granted
Nov 11, 2025
Kind
B2
Abstract

A fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (T reg ) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.

Claims (11)

1 . A method of treating HvG disease in a patient, comprising administering to said patient a fusion protein comprising a single-chain variable fragment antibody domain (scFv), a hinge, a transmembrane domain, an intracellular hCD28 signalling domain and an intracellular hCD3ζ (hCD3 zeta) signalling domain forming a chimeric antigen receptor having specificity for HLA-A*02 (CAR-A*02), wherein the fusion protein is expressed in a CD4+CD25+CD127low human regulatory T (Treg) cell, which Treg that express the CAR-A*02 is HLA-A*02 negative, wherein the patient is HLA-A*02 negative and contains or is intended to contain a solid tissue transplant which is HLA-A*02 positive.

2 . The method according to claim 1 , wherein the hinge and the transmembrane domain of the fusion protein have an amino acid sequence of SEQ ID NO: 13, the hCD28 signalling domain has an amino acid sequence of SEQ ID NO: 14, and the hCD3ζ (hCD3 zeta) signalling domain has an amino acid sequence of SEQ ID NO: 15.

3 . The method according to claim 1 , wherein the hinge and the transmembrane domain, which is a CD8 transmembrane domain, of the fusion protein have an amino acid sequence of SEQ ID NO: 13, the hCD28 signalling domain has an amino acid sequence of SEQ ID NO: 14, and the hCD3 ζ domain has an amino acid sequence of SEQ ID NO: 15, or the hCD28 signalling domain including the hCD3ζ signalling domain have an amino acid sequence of SEQ ID NO: 21.

4 . The method according to claim 1 , wherein the single-chain variable fragment antibody domain of the fusion protein has an amino acid sequence which is selected-from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12.

5 . The method according to claim 1 , wherein the fusion protein comprises or consists of, from N-terminal to C-terminal, one scFv domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12, a hinge and a transmembrane domain having an amino acid sequence of SEQ ID NO: 13, a hCD28 signalling domain having an amino acid sequence of SEQ ID NO: 14, and a hCD3ζ (hCD3 zeta) signalling domain having an amino acid sequence of SEQ ID NO: 15.

6 . The method according to claim 1 , wherein the fusion protein is expressed from a nucleic acid sequence encoding the fusion protein together with an additional N-terminal secretory leader peptide comprising SEQ ID NO: 24 or SEQ ID NO: 25.

7 . The method according to claim 1 , wherein the Treg is genetically manipulated additionally to express FOXP3.

8 . The method according to claim 7 , wherein the expression of the FOXP3 is constitutive.

9 . The method according to claim 1 , wherein the fusion protein is characterized by providing suppressor activity to a CD4 + CD25 + CD127 low HLA-A*02 negative human regulatory T (Treg) cell in the presence of HLA-A*02 positive solid tissue.

10 . The method according to claim 1 , wherein the fusion protein is characterized in that the Treg cell is genetically manipulated to express a caspase-9 dimerizer system.

11 . A method of treating HvG disease in a patient, comprising administering to said patient a CD4+CD25+CD127low and HLA-A*02 negative human regulatory T (Treg) cell expressing a fusion protein comprising a single-chain variable fragment antibody domain (scFv), a hinge, a transmembrane domain, an intracellular hCD28 signalling domain and an intracellular hCD3ζ (hCD3 zeta) signalling domain forming a chimeric antigen receptor having specificity for HLA-A*02 (CAR-A*02) wherein the Treg is genetically manipulated additionally to express FOXP3 and wherein the patient is HLA-A*02 negative and contains or is intended to contain a solid tissue transplant which is HLA-A*02 positive.

Assignments (2)
LICENSE Recorded Nov 17, 2022
From: MEDIZINISCHE HOCHSCHULE HANNOVER; TECHNISCHE UNIVERSITÄT BRAUNSCHWEIG
To: QUELL THERAPEUTICS LIMITED
Reel/Frame 061809/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: JÄCKEL, ELMAR; NOYAN, FATIH; HUST, MICHAEL
To: MEDIZINISCHE HOCHSCHULE HANNOVER; TECHNISCHE UNIVERSITÄT BRAUNSCHWEIG
Reel/Frame 057726/0864 →
Priority Claims (1)
EP 16177208 · Jun 30, 2016 · regional
Continuity (2)
Continuation 16310312
Related Publication 20220133796A1 · May 5, 2022
References Cited (25)
US 11160831B2 · Jäckel · 2021 [cited by examiner]
US 20180282416A1 · Riley · 2018 [cited by examiner]
WO 2008095141A2 · 2008 [cited by applicant]
WO 2013104804A2 · 2013 [cited by applicant]
WO 2015123642A1 · 2015 [cited by applicant]
Tang et al. (Curr Opin Organ Transplant 2012, 17:349-354). (Year: 2012). [cited by examiner]
Joffre et al. (Nature medicine, 14(1), 88-92, 2008). (Year: 2008). [cited by examiner]
Lechler et al. (Nature medicine, 11(6), 605-613 (2005)). (Year: 2005). [cited by examiner]
Matthias Edinger (J Clin Invest. 2016; 126(4): 1248-1250). (Year: 2016). [cited by examiner]
Fransson et al., “CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery”, Journal of Neuroinflammation, 2012, pp. 1-12, vol. 9, No. 112, BioMed Central. [cited by applicant]
Extended European Search Report from the corresponding European Patent Application No. 21158543.5, dated Aug. 24, 2021. [cited by applicant]
Chinese Office Action from the corresponding Chinese Patent Application No. 201780041028.1, dated Jan. 10, 2022. [cited by applicant]
Chinese Office Action from the corresponding Chinese Patent Application No. 201780041028.1, dated Jul. 8, 2022. [cited by applicant]
Macdonald et al., “Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor”, The Journal of Clinical Investigation, 2016, pp. 1413-1424, vol. 126, No. 4, American Society for Clinical Investig… [cited by applicant]
Naguma et al., “Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H”, Gene Therapy, 2014, pp. 575-584, vol. 21, Macmillan Pu… [cited by applicant]
Noyan et al., “Isolation of human antigen-specific regulatory T cells with high suppressive function”, European Journal of Immunology, 2014, pp. 2592-2602, vol. 44, WILEY-VCH Verlag Gmbh & Co. KGaA, Weinheim. [cited by applicant]
Galla et al. “Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery”, Nucleic Acids Research, 2011. pp. 7147-7160, vol. 39, No. 16, Oxford University Press. [cited by applicant]
Di Stasi et al., “Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy”, The New England Journal of Medicine, 2011, pp. 1673-1683, vol. 365, No. 18, National Institutes of Health. [cited by applicant]
Long et al., “Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects”, Diabetes, 2010, pp. 407-415, vol. 59, No. 2, American Diabe… [cited by applicant]
Hombach et al., “Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unint… [cited by applicant]
Reyes et al., “Characterization of swine leucocyte antigen alleles in a crossbred pig to be used in xenotransplant studies”, Tissue Antigens, 2014, pp. 484-488, vol. 84, John Wiley & Sons Ltd. [cited by applicant]
Watkins et al., “The isolation and characterisation of human monoclonal HLA-A2 antibodies from an immune V gene phage display library”, Tissue Antigens, 2000, pp. 219-228, vol. 55, Munksgaard. [cited by applicant]
Elinav et al., “Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor”, Gastroenterology, 2009, pp. 1721-1731, vol. 136, No. 5, AGA Institute. [cited by applicant]
Noyan et al., “Induced transgene expression for the treatment of solid tumors by hematopoietic stem cell-based gene therapy”, Cancer Gene Therapy, 2012, pp. 352-357, vol. 19, Macmillan Publishers Limited. [cited by applicant]
International Search Report and Written Opinion from the priority International Patent Application No. PCT/EP2017/065472, dated Sep. 1, 2017. [cited by applicant]